Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection

Alembic Pharmaceuticals has received final USFDA approval. This approval is for its generic Doxorubicin Hydrochloride Liposome injection. The injection comes in strengths of 20 mg/10 mL and 50 mg/25 mL. It is used to treat ovarian cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma. The market size for this injection is estimated at USD 29 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CWsE2vP
via IFTTT

0 comments:

Post a Comment